newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

JBIO
  • JADE101 demonstrated approximately 70% IgA reductions sustained at 12 weeks following a single dose in a Phase 1 trial for IgA nephropathy.
  • Greater than 70% IgA reductions are projected at steady state with a single subcutaneous maintenance injection every 12 weeks.
  • The IgA-lowering effect of JADE101 is faster, deeper, & more durable compared to first-generation anti-APRIL or dual APRIL/BAFF agents.
  • JADE101 achieved an IgA-lowering potency estimated to be approximately 379-fold higher than sibeprenlimab & approximately 26-fold higher than povetacicept.
  • The drug showed a half-life at steady state approximately 8.7-fold longer than povetacicept & 2.6-fold longer than sibeprenlimab.
  • JADE101 was well-tolerated across all evaluated subcutaneous doses up to 1,400 mg with no serious adverse events or cases of hypogammaglobulinemia.
  • The ongoing Phase 2 JUNIPER trial is enrolling approximately 30 participants with interim clinical data expected in 2027.
  • A Phase 3 registrational trial is planned to initiate in the first half of 2027, pending FDA requirements.
  • Interim results will be presented at the 63rd European Renal Association Congress in Glasgow from June 3-6, 2026.
  • Jade Biosciences will host a webcast & conference call on June 1, 2026, at 8:00 a.m. ET to discuss the data.